Pfizer
Pfizer Inc., a leading global biopharmaceutical company headquartered in the United States, has been at the forefront of medical innovation since its founding in 1849. With a strong presence in North America, Europe, and Asia, Pfizer operates across various sectors, including vaccines, oncology, and rare diseases. The company is renowned for its core products, such as the COVID-19 vaccine and groundbreaking cancer therapies, which leverage advanced biotechnology to address unmet medical needs. Pfizer's commitment to research and development has positioned it as a market leader, consistently achieving significant milestones in drug discovery and patient care. With a robust portfolio and a reputation for quality, Pfizer continues to shape the future of healthcare, making a profound impact on global health outcomes.
DitchCarbon Score
How does Pfizer's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pfizer's score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pfizer's reported carbon emissions
In 2024, Pfizer reported total emissions of approximately 1,080,000,000 kg CO2e, which includes 1,080,000,000 kg CO2e from Scope 1 and 2 emissions, and approximately 342,000,000 kg CO2e from Scope 3 emissions related to business travel and downstream transportation and distribution. In 2023, Pfizer's emissions in the US were significant, with Scope 1 emissions at approximately 399,241,000 kg CO2e and Scope 2 emissions at approximately 342,804,000 kg CO2e. Pfizer has set ambitious climate commitments, aiming for a 46% reduction in Scope 1 and 2 emissions by 2030 from a 2019 baseline. This target is part of their broader goal to achieve net-zero emissions across their operations by 2040. Additionally, they aim to reduce Scope 3 emissions related to business travel by 25% and upstream transportation and distribution by 10% by 2025, both from a 2019 baseline. The company is also committed to sourcing 100% renewable electricity by 2030 and ensuring that 64% of their suppliers by spend covering purchased goods and services have science-based targets by 2025. These initiatives reflect Pfizer's dedication to sustainability and reducing its carbon footprint in alignment with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
| Scope 2 | - | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | - | - | - |
| Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pfizer is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
